


Appl. No. 09/925,816

Attorney Docket No. 10114-009

I. Listing of Claims

1. (Currently Amended): A [[sugar-modified]] linsidomine compound (SIN-1) comprising a sugar moiety, a SIN-1 moiety and a glycosidic bond disposed between the sugar and SIN-1 moieties, said [[sugar-modified]] linsidomine compound SIN-1 having the general structure



wherein L is a bond or a bifunctional linker group and wherein R is the sugar moiety and can comprise [[any]] a carbohydrate.

2. (Currently Amended): The [[sugar-modified]] linsidomine compound SIN-1 according to claim 1, wherein L is a bifunctional linker group.

3. (Currently Amended): The [[sugar-modified]] linsidomine compound SIN-1 according to claim 2, wherein the linker group is a carbonyl containing group.

4. (Currently Amended): The [[sugar-modified]] linsidomine compound SIN-1 according to claim 1, wherein R is a monosaccharide.

5. (Currently Amended): The [[sugar-modified]] linsidomine compound SIN-1 according to claim 4, wherein R is selected from the group consisting of glyceraldehyde, erythrose, threose, ribose, arabinose, xylose, lyxose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, and tagatose.

6. (Currently Amended): The [[sugar-modified]] linsidomine compound SIN-1 according to claim 4, wherein R is glucose.

7. (Currently Amended): The [[sugar-modified]] linsidomine compound SIN-1 according to claim 4, wherein R is galactose.

BRINKS
HOFFER
GILSON
BLTONE

Appln. No. 09/925,816

Attorney Docket No. 10114-009

8. (Currently Amended): The [[sugar-modified]] linsidomine compound SIN-1 according to claim 4, wherein R is a furanose or pyranose ring structure.

9. (Currently Amended): The [[sugar-modified]] linsidomine compound SIN-1 according to claim 1, wherein R is a disaccharide.

10. (Currently Amended): The [[sugar-modified]] linsidomine compound SIN-1 according to claim 9, wherein R is a member selected from the group consisting of sucrose, lactose, and maltose.


11. (Currently Amended): The [[sugar-modified]] linsidomine compound SIN-1 according to claim 1, wherein L is a glycosidic bond.

12. (Currently Amended): The [[sugar-modified]] linsidomine compound SIN-1 according to claim 11, wherein the glycosidic bond is in an a configuration.

13. (Currently Amended): The [[sugar-modified]] linsidomine compound SIN-1 according to claim 11, wherein the glycosidic bond is in a P configuration.

14. (Original): A compound which is N-(β -D-glucopyranosyl)-carbonyl-3-morpholinosydnonimine, N-(α -glucopyranosyl)-carbonyl-3-morpholinosydnonimine, N-(β -D-galactopyranosyl)-carbonyl-3-morpholinosydnonimine, or N-(α -D-galactopyranosyl)-carbonyl-3-morpholinosydnonimine.

15. (Currently Amended): A pharmaceutical composition; comprising:
a therapeutically effective amount of a [[first sugar-modified]] linsidomine compound SIN-1, the linsidomine compound (SIN-1) comprising a sugar moiety, a SIN-1 moiety and a glycosidic bond disposed between the sugar and SIN-1 moieties, the linsidomine compound SIN-1 having the general structure




BRINKS
HOFFER
GILSON
ALLONE

Appln. No. 09/925,816

Attorney Docket No. 10114-009

wherein L is a bond or a bifunctional linker group and wherein R is the sugar moiety and can comprise a carbohydrate; and
a pharmaceutically acceptable carrier.

16. (Currently Amended): A pharmaceutical composition in accordance with claim 15, further comprising a therapeutically effective amount of a second [[sugar-modified]] linsidomine compound SIN-1, the second linsidomine compound (SIN-1) comprising a sugar moiety, a SIN-1 moiety and a glycosidic bond disposed between the sugar and SIN-1 moieties, the second linsidomine compound SIN-1 having the general structure



wherein L is a bond or a bifunctional linker group and wherein R is the sugar moiety and can comprise a carbohydrate.

17. (Original): A pharmaceutical composition according to claim 15, wherein the carrier comprises a liquid vehicle.

18. (Original): A pharmaceutical composition according to claim 17, wherein the liquid vehicle comprises a member selected from the group consisting of water, Ringers-Lactate, DMSO, ethanol, and glycerol.

19. (Original): A pharmaceutical composition according to claim 15, wherein the carrier comprises one or more pharmaceutically acceptable excipients.

20. (Original): A pharmaceutical composition according to claim 19, wherein said composition is in the form of a pill, tablet, lacquered tablet, coated tablet, hard gelatin capsule, soft gelatin capsule, solution, syrup, emulsion, suspension, aerosol, suppository, ointment, gel, or a paste.

21. (Cancelled)

BRINKS
HOFFER
GILSON
& LIONE

-4-

Appln. No. 09/925,816

Attorney Docket No. 10114-009

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)

31. (Cancelled)

32. (Cancelled)

33. (Cancelled)

BRINKS
HOFER
GILSON
ALIONE